Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bright-01: QL1706 plus Disitamab Vedotin in cisplatin-resistant or -intolerant locally advanced/metastatic penile squamous cell carcinoma
ChiCTR2600117965Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 and disitamab vedotin in penile squamous cell carcinoma (PSCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Objective Response Rate. Started Jan 2026; status: recruiting.
02
Drugs
QL1706disitamab vedotin
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on ChiCTR2600117965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117965.